Becton Dickinson and Co (BDX) Holdings Raised by South State Corp

South State Corp raised its holdings in shares of Becton Dickinson and Co (NYSE:BDX) by 1.8% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 13,051 shares of the medical instruments supplier’s stock after purchasing an additional 235 shares during the quarter. South State Corp’s holdings in Becton Dickinson and were worth $2,940,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of BDX. Vanguard Group Inc. lifted its holdings in Becton Dickinson and by 1.3% during the 3rd quarter. Vanguard Group Inc. now owns 21,666,262 shares of the medical instruments supplier’s stock worth $5,654,895,000 after buying an additional 283,433 shares during the last quarter. Vanguard Group Inc lifted its holdings in Becton Dickinson and by 1.3% during the 3rd quarter. Vanguard Group Inc now owns 21,666,262 shares of the medical instruments supplier’s stock worth $5,654,895,000 after buying an additional 283,433 shares during the last quarter. BlackRock Inc. lifted its holdings in Becton Dickinson and by 1.9% during the 4th quarter. BlackRock Inc. now owns 19,384,283 shares of the medical instruments supplier’s stock worth $4,367,665,000 after buying an additional 355,223 shares during the last quarter. FMR LLC lifted its holdings in Becton Dickinson and by 8.0% during the 3rd quarter. FMR LLC now owns 17,354,031 shares of the medical instruments supplier’s stock worth $4,529,401,000 after buying an additional 1,286,579 shares during the last quarter. Finally, Oregon Public Employees Retirement Fund lifted its holdings in Becton Dickinson and by 22,485.4% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 6,574,612 shares of the medical instruments supplier’s stock worth $29,000 after buying an additional 6,545,502 shares during the last quarter. Hedge funds and other institutional investors own 83.96% of the company’s stock.

Shares of NYSE BDX opened at $254.37 on Friday. The company has a market capitalization of $67.17 billion, a P/E ratio of 23.10, a P/E/G ratio of 1.76 and a beta of 1.23. Becton Dickinson and Co has a 12-month low of $208.62 and a 12-month high of $265.87. The company has a debt-to-equity ratio of 0.83, a quick ratio of 0.62 and a current ratio of 0.97.

Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings results on Tuesday, February 5th. The medical instruments supplier reported $2.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.58 by $0.12. The business had revenue of $4.16 billion for the quarter, compared to the consensus estimate of $4.10 billion. Becton Dickinson and had a return on equity of 14.65% and a net margin of 5.69%. The business’s revenue was up 35.1% on a year-over-year basis. During the same quarter last year, the business posted $2.48 EPS. On average, research analysts forecast that Becton Dickinson and Co will post 12.1 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, March 29th. Investors of record on Friday, March 8th will be issued a $0.77 dividend. This represents a $3.08 annualized dividend and a dividend yield of 1.21%. The ex-dividend date of this dividend is Thursday, March 7th. Becton Dickinson and’s dividend payout ratio (DPR) is 27.97%.

A number of research analysts have commented on BDX shares. TheStreet raised Becton Dickinson and from a “c+” rating to an “a” rating in a report on Tuesday, February 5th. Zacks Investment Research raised Becton Dickinson and from a “hold” rating to a “buy” rating and set a $243.00 target price on the stock in a report on Tuesday, January 8th. Citigroup reduced their target price on Becton Dickinson and from $289.00 to $279.00 and set a “buy” rating on the stock in a report on Tuesday, November 13th. Deutsche Bank started coverage on Becton Dickinson and in a report on Thursday, December 6th. They set a “buy” rating and a $280.00 target price on the stock. Finally, Morgan Stanley reduced their target price on Becton Dickinson and from $265.00 to $240.00 and set an “equal weight” rating on the stock in a report on Wednesday, January 2nd. Six equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $253.17.

In related news, CEO Vincent A. Forlenza sold 11,340 shares of the firm’s stock in a transaction that occurred on Monday, February 25th. The stock was sold at an average price of $250.40, for a total value of $2,839,536.00. Following the sale, the chief executive officer now owns 227,250 shares of the company’s stock, valued at approximately $56,903,400. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 0.12% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Becton Dickinson and Co (BDX) Holdings Raised by South State Corp” was reported by Community Financial News and is the property of of Community Financial News. If you are reading this story on another site, it was illegally copied and reposted in violation of US and international copyright & trademark laws. The correct version of this story can be accessed at https://www.com-unik.info/2019/03/03/becton-dickinson-and-co-bdx-holdings-raised-by-south-state-corp.html.

Becton Dickinson and Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Recommended Story: Why do companies issue stock splits?

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit